Bleomycin (BLM) is an anti‑cancer drug that has toxic side effects on the lungs. It induces DNA strand breaks and oxidative stress, thereby causing parenchymal inflammation, epithelial cell injury accompanied by reactive hyperplasia, epithelial‑mesenchymal transition, fibroblast activation and differentiation into myofibroblasts, as well as damage to the basement membrane and alveolar epithelium.
Fig.1 Bleomycin induced pulmonary fibrosis in C57BL/6 (male, 10-12w) mice. (A) Body Weight. (B) Body Weight Change. (C) Survival Curve.
Fig2.Bleomycin induced pulmonary fibrosis in C57BL/6 (male, 10-12w) mice. (A) H&E and Masson stain. (B) Alveolar inflammation score. (C)Alveolar fibrosis score.
